目的 探讨利妥昔单抗联合改良CHOP方案治疗胃肠道非霍奇金淋巴瘤的疗效及其安全性.方法 选择2014年1月至2016年1月医院确诊胃肠道非霍奇金淋巴瘤并接受治疗的患者80例,随机分为两组,各40例,对照组患者予以改良CHOP方案治疗,观察组患者予以利妥昔单抗联合改良CHOP方案.观察两组患者的治疗有效率、平均缓解时间和不良反应发生情况.结果 观察组患者治疗有效率较对照组显著升高(P0.05).结论 利妥昔单抗联合改良CHOP方案治疗胃肠道非霍奇金淋巴瘤疗效明显,可促进病情缓解,安全性较高,临床可推广.%Objective To investigate the clinical efficacy and safety of rituximab combined with modified CHOP regimen in treating non-Hodgkin′s lymphoma. Methods Totally 80 patients with gastrointestinal non-Hodgkin′s lymphoma in our hospital from January 2014 to January 2016 were divided into the observation group ( n=40 ) and the control group ( n=40 ) . The control group was given modified CHOP regimen, while the observation group was given modified CHOP regimen combined with rituximab. The effective rate, mean complete response time and the adverse reaction were observed in the two groups. Results The effective rate of the observation was significantly higher than that of the control group ( P 0. 05 ) . Conclusion Rituximab combined with modified CHOP regimen in treating non-Hodgkin′s lymphoma can significantly improve the clinical efficacy and the complete response time, it is safety and worthy of clinical promotion.
展开▼
